Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Chagas disease Indication Strategy Report 2026: Trypanosoma cruzi CYP51, Trials and Deals
23 July 2026
2026 Chagas disease strategy: epidemiology, Trypanosoma cruzi CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Leishmaniasis Indication Strategy Report 2026: Leishmania CYP51, Trials and Deals
23 July 2026
2026 Leishmaniasis strategy: epidemiology, Leishmania CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary membranous nephropathy Indication Strategy Report 2026: PLA2R, Trials and Deals
23 July 2026
2026 Primary membranous nephropathy strategy: epidemiology, PLA2R biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Familial renal glucosuria Indication Strategy Report 2026: SGLT2, Trials and Deals
23 July 2026
2026 Familial renal glucosuria strategy: epidemiology, SGLT2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Antenatal Bartter syndrome Indication Strategy Report 2026: NKCC2, Trials and Deals
23 July 2026
2026 Antenatal Bartter syndrome strategy: epidemiology, NKCC2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary distal renal tubular acidosis Indication Strategy Report 2026: AE1, Trials and Deals
23 July 2026
2026 Primary distal renal tubular acidosis strategy: epidemiology, AE1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Congenital anomalies of kidney and urinary tract Indication Strategy Report 2026: RET, Trials and Deals
23 July 2026
2026 Congenital anomalies of kidney and urinary tract strategy: epidemiology, RET biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Immunotactoid glomerulopathy Indication Strategy Report 2026: CD20, Trials and Deals
23 July 2026
2026 Immunotactoid glomerulopathy strategy: epidemiology, CD20 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Congenital nephrotic syndrome Indication Strategy Report 2026: NPHS1, Trials and Deals
23 July 2026
2026 Congenital nephrotic syndrome strategy: epidemiology, NPHS1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Fibrillary glomerulonephritis Indication Strategy Report 2026: DNAJB9, Trials and Deals
23 July 2026
2026 Fibrillary glomerulonephritis strategy: epidemiology, DNAJB9 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Dense deposit disease Indication Strategy Report 2026: Complement C3, Trials and Deals
23 July 2026
2026 Dense deposit disease strategy: epidemiology, Complement C3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Steroid-resistant nephrotic syndrome Indication Strategy Report 2026: APOL1, Trials and Deals
23 July 2026
2026 Steroid-resistant nephrotic syndrome strategy: epidemiology, APOL1 biology, clinical competition, recent deals, unmet need and market attractiveness.